IL276287A - Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of buzzing, Sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD and addiction - Google Patents
Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of buzzing, Sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD and addictionInfo
- Publication number
- IL276287A IL276287A IL276287A IL27628720A IL276287A IL 276287 A IL276287 A IL 276287A IL 276287 A IL276287 A IL 276287A IL 27628720 A IL27628720 A IL 27628720A IL 276287 A IL276287 A IL 276287A
- Authority
- IL
- Israel
- Prior art keywords
- amino
- carboxylic acid
- difluoromethylenyl
- difluoromethylidene
- meniere
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862628020P | 2018-02-08 | 2018-02-08 | |
| US201862628541P | 2018-02-09 | 2018-02-09 | |
| PCT/US2019/017201 WO2019157273A1 (en) | 2018-02-08 | 2019-02-08 | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL276287A true IL276287A (en) | 2020-09-30 |
Family
ID=67475310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL276287A IL276287A (en) | 2018-02-08 | 2020-07-26 | Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of buzzing, Sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD and addiction |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10653652B2 (https=) |
| EP (1) | EP3735237A4 (https=) |
| JP (1) | JP2021512920A (https=) |
| KR (3) | KR20250167147A (https=) |
| CN (1) | CN112261938A (https=) |
| AU (1) | AU2019216742B2 (https=) |
| CA (1) | CA3090258A1 (https=) |
| IL (1) | IL276287A (https=) |
| MX (1) | MX2020008359A (https=) |
| WO (1) | WO2019157273A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016342027B2 (en) | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| PL3615019T3 (pl) | 2017-04-26 | 2026-01-19 | Navitor Pharmaceuticals, Inc. | Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie |
| US11771671B2 (en) | 2018-02-08 | 2023-10-03 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction |
| JP2021519753A (ja) * | 2018-03-29 | 2021-08-12 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 眼障害の治療における（１ｓ，３ｓ）−３−アミノ−４−（ジフルオロメチリデン）シクロペンタン−１−カルボン酸および（ｓ）−３−アミノ−４−（ジフルオロメチルエニル）シクロペンタ−１−エン−１−カルボン酸の使用 |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) * | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US6656172B1 (en) * | 2002-09-27 | 2003-12-02 | Medtronic, Inc. | Method for treating severe tinnitus |
| JP2009517393A (ja) | 2005-11-28 | 2009-04-30 | オレキシジェン・セラピューティクス・インコーポレーテッド | 不安症の治療方法 |
| CA2790820A1 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US20130230586A1 (en) * | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| WO2013087090A1 (en) * | 2011-12-12 | 2013-06-20 | Auris Medical Ag | Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system |
| EP2806867A4 (en) * | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| JP6841821B2 (ja) | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
| EP4692048A3 (en) | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
-
2019
- 2019-02-08 KR KR1020257038778A patent/KR20250167147A/ko active Pending
- 2019-02-08 KR KR1020247034793A patent/KR20240154700A/ko not_active Ceased
- 2019-02-08 CN CN201980023215.6A patent/CN112261938A/zh active Pending
- 2019-02-08 MX MX2020008359A patent/MX2020008359A/es unknown
- 2019-02-08 US US16/270,856 patent/US10653652B2/en active Active
- 2019-02-08 KR KR1020207025754A patent/KR20210007948A/ko not_active Ceased
- 2019-02-08 EP EP19750667.8A patent/EP3735237A4/en active Pending
- 2019-02-08 JP JP2020542858A patent/JP2021512920A/ja active Pending
- 2019-02-08 WO PCT/US2019/017201 patent/WO2019157273A1/en not_active Ceased
- 2019-02-08 CA CA3090258A patent/CA3090258A1/en active Pending
- 2019-02-08 AU AU2019216742A patent/AU2019216742B2/en active Active
-
2020
- 2020-07-26 IL IL276287A patent/IL276287A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112261938A (zh) | 2021-01-22 |
| KR20240154700A (ko) | 2024-10-25 |
| KR20250167147A (ko) | 2025-11-28 |
| EP3735237A4 (en) | 2021-03-17 |
| AU2019216742B2 (en) | 2024-05-09 |
| US10653652B2 (en) | 2020-05-19 |
| KR20210007948A (ko) | 2021-01-20 |
| CA3090258A1 (en) | 2019-08-15 |
| WO2019157273A1 (en) | 2019-08-15 |
| EP3735237A1 (en) | 2020-11-11 |
| JP2021512920A (ja) | 2021-05-20 |
| MX2020008359A (es) | 2020-11-24 |
| AU2019216742A1 (en) | 2020-08-13 |
| US20190240174A1 (en) | 2019-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276287A (en) | Use of (1S,3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of buzzing, Sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD and addiction | |
| IL276494A (en) | Niraprib formulations for children and methods for treating children | |
| PH12019501575A1 (en) | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF | |
| AU2018295515A1 (en) | Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes | |
| IL280779A (en) | Methods of decreasing dysbiosis and restoring a microbiome | |
| SG11202008938WA (en) | Hair and scalp diagnosis & treatment | |
| HK1246419A1 (zh) | 用於自适应医疗决策支持的系统和方法 | |
| GB201915522D0 (en) | Use of cannabidiol preparations in the treatment of absence epilepsy | |
| MX2023014145A (es) | Oligonucleotidos modificados y metodos de uso. | |
| HUE056471T2 (hu) | Dalargin akut légzõszervi vírusos fertõzések kezelésében történõ alkalmazásra | |
| IL277599A (en) | Use of (1S, 3S)-3-amino-4-(difluoromethylidene)cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopentane-1-ene-1-carboxylic acid in the treatment of eye disorders | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| MX395572B (es) | Anticuerpos anti-htra1 y metodos de uso de los mismos | |
| HUE059149T2 (hu) | 2,4-Diaminokinazolin származékok és azok alkalmazása vírusfertõzések, rák vagy allergiák kezelésében | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| IL270701A (en) | Neurotrophins for use in the treatment of hearing loss | |
| IL270762B (en) | Wound dressing comprising a combination of hydrogel and honey, method of preparation and uses thereof | |
| EA201991488A1 (ru) | Модуляторы калиевых каналов | |
| EP4606387A3 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
| WO2013138338A3 (en) | Methods for treating tissue damage associated with ischemia with apoliporotein d | |
| Spero et al. | Running the numbers: the maldistribution of health care providers in rural and underserved areas in North Carolina | |
| HK40040896A (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction | |
| GB201910299D0 (en) | Medical uses, methods and uses | |
| GB201907832D0 (en) | Medical uses, methods and uses | |
| KR102419010B9 (ko) | 인공 치아 시술 정보 제공 시스템, 이를 위한 시술자 장치 및 이를 이용한 인공 치아 시술 정보 제공 방법 |